Skip to main content

Advertisement

Table 1 Samples obtained from a commercial brain

From: R-RAS2 overexpression in tumors of the human central nervous system

Histo-Pathology Grade1 Patients Samples Mean age Men (%)
a) Clinicopathologic data of 193 human CNS samples
Brain tissue - 13 23 35,3 ± 19,2 38,5
Hyperplasia - 2 3 34,7 ± 8,1 50
Mixed glioma - 2 4 41 ± 3,5 100
Glioblastoma III 7 13 60,5 ± 14,4 85,7
  IV 9 15 49,5 ± 16,9 66,6
Astrocytoma I 32 59 37,6 ± 10,3 69,6
  II 28 54 43,5 ± 14,2 60,7
  III 5 9 44,4 ± 7,3 20
Oligodendroglioma I-II 2 4 29,5 ± 0,6 50
  II-III 3 5 57,4 ± 15,1 100
  III 2 4 42,5 ± 11 100
b) Clinicopathologic data of 56 human CNS tumor samples
Medulloblastoma IV 6 18 8,8 ± 5 66,6
Cerebroma IV 3 9 26,6 ± 16,9 33,3
Meningioma IV 4 11 40 ± 9,5 75
Ependymoma IV 1 3 14 ± 0 100
Undifferenciated IV 5 15 11,2 ± 4 60
Histo-Pathology Grade 1 Patients Mean age Men (%)
c) Clinicopathologic data of 32 human CNS samples
Brain tissue - 1 55 0
Hyperplasia - 1 45 ± 0 100
Astrocytoma I 1 27 ± 0 0
  II 2 39,5 ± 19,1 50
  III 3 35 ± 4,6 100
Oligoastrocytoma II 1 37 ± 0 0
  III 1 41 ± 0 100
Oligodendroglioma II 1 33 ± 0 100
  III 3 45,3 ± 5,1 0
Ependymoma III 1 49 ±0 0
Meningioma I 13 53,8 ± 13,6 38,5
  II 4 61 ± 11,2 50
  1. 1Classified according to the WHO criteria.